Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center

Pediatric Hematology and Oncology

Volumn 24, Issue 6, 2007, Pages 417-430

  Karadeniz, Ceyda ^a   Oguz, Aynur ^a   Citak, Elvan Caglar ^a,b   Uluoglu, Omer ^a   Okur, Visal ^a   Demirci, Selda ^a   Okur, Arzu ^a   Aksakal, Nur ^a  

^a GAZI UNIVERSITY   (Turkey)

^b Kuzgun Sokak   (Turkey)

Author keywords

BFM protocol; Chemotherapy; Childhood; Non Hodgkin lymphoma

Indexed keywords

FOLINATE CALCIUM; METHOTREXATE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ANALYTIC METHOD; ARTICLE; B CELL LYMPHOMA; CANCER PATIENT; CANCER STAGING; CHILD; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PEDIATRICS; RISK FACTOR; UNIVARIATE ANALYSIS;

ADOLESCENT; ALLOPURINOL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DIURETICS; FEMALE; FLUID THERAPY; HEMATOLOGIC DISEASES; HUMANS; KAPLAN-MEIERS ESTIMATE; L-LACTATE DEHYDROGENASE; LEUCOVORIN; LYMPHOMA, B-CELL; MALE; METHOTREXATE; MUCOSITIS; NEOPLASM PROTEINS; RISK ASSESSMENT; SODIUM BICARBONATE; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR LYSIS SYNDROME; TURKEY; VINCRISTINE;

EID: 34548126143     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010701450972     Document Type: Article

References (21)

1. Patte C, Philip T, Rodary C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol.. 1991;9:123-132.
2. Patte C, Auperin A, Michon J, et al. The Société Francaise d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97:3370-3379.
3. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage. A report of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 1995;13:359-372.
4. Reiter A, Schrappe M, TiemannM, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group trial NHL BFM 90. Blood. 1999;94:3294-3306.
5. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105:948-958.
6. Anderson JR, Jenkin RD, Wilson JF, et al. Long-term follow-up of patients treated with COMP or LSA2-L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Children's Cancer Study Group. J Clin Oncol. 1993;11:1024-1032.
7. Muller-Weihrich S, Beck J, Henze G, et al. BFM studie 1981/1983 zur Behandlung hochmaligner Non-Hodgkin-Lymphome bei Kindern: Ergebnisse einer nach histologisch-immunologischem Typ und Ausbreitungsstadium stratifizierten Therapie. Klin Padiatr. 1984;196:135-142.
8. Sarialioglu F, Buyukpamukcu M, Akyuz C, Kutluk T. Combined chemotherapy in Non-Burkitt's non-Hodgkin's lymphoma: long term results of a unified protocol. Med Pediatr Oncol.. 1993;21:532.
9. Wessels G, Hesseling PB. High dose intense chemotherapy in South African children with B-cell lymphoma: morbidity, supportive measures and outcome. Med Pediatr Oncol. 2000;34:143-146.
10. Kavan P, Kabickova E, Gajdos P, et al. Treatment of pediatric B-cell non-Hodgkin's lymphomas at the Motol Hospital in Praque, Czech Republic: results based on the NHL BFM 90 protocols. Pediatr Hematol Oncol. 1999;16:201-212.
11. Klumb CE, Schramm MT, De Rense LM, et al. Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil. J Pediatr Hematol Oncol.. 2004;26:462-468.
12. Acquatella G, Insausti CL, Garcia R, et al. Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol. Pediatr Blood Cancer.. 2004;43:580-586.
13. Chantada G, Casak S, Alderete D, et al. Treatment of B-cell malignancies in children with a modified BFM-NHL 90 protocol in Argentina. Med Pediatr Oncol. 2003;41:488-490.
14. Kutluk T, Varan A, Akyuz C, Buyukpamukcu M. Clinical characteristics and treatment results of LMB/LMT regimen in children with non-Hodgkin's lymphoma. Cancer Invest. 2002;20:626-633.
15. Stansfeld AG, Diebold J, Kapanci Y, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292-293.
16. Murphy SB, Fairclough DL, Hutchinson RE, Berard CW. Non-Hodgkin's lymphoma of childhood: an analysis of the histology, staging and response to treatment of 388 cases at single institution. J Clin Oncol. 1989;7:186-193.
17. Buyukpamukcu M. Non-Hodgkin's lymphomas. In: Voute P, Kalifa C, Barrett A, eds. Cancer in Children. Oxford, UK: Oxford University Press; 1998:119-136.
18. Link MP, Weinstein HJ. Malignant non-Hodgkin lymphomas in children. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott; 2006:722-747.
19. Anderson JR, Wilson JF, Jenkin DT, et al. Childhood non-Hodgkin's lymphoma: the results of a randomized trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med. 1983;308:559-565.
20. Okur FV, Oguz A, Karadeniz C, et al. Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt non-Hodgkin lymphoma. Pediatr Hematol Oncol.. 2006;23:25-31.
21. Ian JC. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without reducing malignant cell in the central nervous system. Pediatr Hematol Oncol. 2004;26:156-163.